CN116675620A - No供体化合物及其制备方法、药物组合物和应用 - Google Patents
No供体化合物及其制备方法、药物组合物和应用 Download PDFInfo
- Publication number
- CN116675620A CN116675620A CN202210160994.8A CN202210160994A CN116675620A CN 116675620 A CN116675620 A CN 116675620A CN 202210160994 A CN202210160994 A CN 202210160994A CN 116675620 A CN116675620 A CN 116675620A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- donor
- donor compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 80
- 239000002840 nitric oxide donor Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 23
- 230000002107 myocardial effect Effects 0.000 claims abstract description 19
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 10
- 230000006378 damage Effects 0.000 claims abstract description 10
- 208000014674 injury Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 230000001146 hypoxic effect Effects 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 229940125904 compound 1 Drugs 0.000 claims description 6
- 230000003833 cell viability Effects 0.000 claims description 5
- 229940125782 compound 2 Drugs 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 14
- 206010002660 Anoxia Diseases 0.000 abstract description 11
- 241000976983 Anoxia Species 0.000 abstract description 11
- 230000007953 anoxia Effects 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 79
- -1 (methylnitroso) amino Chemical group 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 23
- 230000007954 hypoxia Effects 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 6
- 229960000201 isosorbide dinitrate Drugs 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000004459 Nitroreductase Human genes 0.000 description 4
- XDSMIEMMZYAJQB-UHFFFAOYSA-N [O-][N+](=O)C1=CC=CC=C1COC(=O)OC1=CC=CC=C1 Chemical compound [O-][N+](=O)C1=CC=CC=C1COC(=O)OC1=CC=CC=C1 XDSMIEMMZYAJQB-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108020001162 nitroreductase Proteins 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000037891 myocardial injury Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- ZFIQGRISGKSVAG-UHFFFAOYSA-N 4-methylaminophenol Chemical compound CNC1=CC=C(O)C=C1 ZFIQGRISGKSVAG-UHFFFAOYSA-N 0.000 description 2
- XFZZDIHCNHYESF-UHFFFAOYSA-N 7-amino-1-bromo-4-phenyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-one Chemical compound C=12CC(=O)C(N)CCC2=C(Br)C=CC=1C1=CC=CC=C1 XFZZDIHCNHYESF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 2
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XHIXVZHYFBOAJT-UHFFFAOYSA-N (2-chloro-4-nitrophenyl)methanol Chemical compound OCC1=CC=C([N+]([O-])=O)C=C1Cl XHIXVZHYFBOAJT-UHFFFAOYSA-N 0.000 description 1
- OAHGNOHGHOTZQU-UHFFFAOYSA-N (4-chloro-2-nitrophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1[N+]([O-])=O OAHGNOHGHOTZQU-UHFFFAOYSA-N 0.000 description 1
- QNJCSIZDJFUHBA-UHFFFAOYSA-N (4-methyl-2-nitrophenyl)methanol Chemical compound CC1=CC=C(CO)C([N+]([O-])=O)=C1 QNJCSIZDJFUHBA-UHFFFAOYSA-N 0.000 description 1
- MHSGOABISYIYKP-UHFFFAOYSA-N (4-nitrophenyl)methyl carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(COC(Cl)=O)C=C1 MHSGOABISYIYKP-UHFFFAOYSA-N 0.000 description 1
- IKEYTRGLCHZQHO-UHFFFAOYSA-N (5-methyl-2-nitrophenyl)methanol Chemical compound CC1=CC=C([N+]([O-])=O)C(CO)=C1 IKEYTRGLCHZQHO-UHFFFAOYSA-N 0.000 description 1
- JKTYGPATCNUWKN-UHFFFAOYSA-N 4-nitrobenzyl alcohol Chemical compound OCC1=CC=C([N+]([O-])=O)C=C1 JKTYGPATCNUWKN-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/04—N-nitroso compounds
- C07C243/06—N-nitroso-amines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
本发明公开了一类NO供体化合物及其制备方法、药物组合物和应用。该化合物结构如式I。该类NO供体化合物及其药物组合物作为缺氧激活型NO供体,可制备为用于治疗心肌缺氧损伤类疾病的药物,所制备药物在细胞水平和动物水平均可以发挥药效,并且该类化合物合成方法简便,易操作。
Description
技术领域
本发明涉及一类NO供体化合物及其制备方法、药物组合物和应用,尤其涉及一类可制备为治疗心肌缺氧损伤类疾病药物的NO供体化合物及其制备方法、药物组合物和应用。
背景技术
冠心病是由冠状动脉器质性狭窄或阻塞造成心肌组织缺血(细胞水平缺氧)引起的心肌损伤,亦称缺血性心脏病。据2020年我国心血管病中心发布的数据报告显示,国内患冠心病等心血管疾病的人数已高达2.9亿。目前冠心病的高发病率和致死率对民众的健康造成了严重的威胁。由于一氧化氮(NO)供体药物可在体内释放外源性NO分子促进血管扩张,因此常用于治疗缺血引起的冠心病。不过现有药物缺乏对缺氧的选择性,不能集中在缺氧部位释放足量的NO,因而带来严重的副作用。
近年来缺氧激活型前药被广泛关注,它可促进活性药物基团在缺氧微环境中选择性的释放,从而降低脱靶毒性。鉴于缺氧是引起心肌损伤的重要因素,将这一设计理念应用于NO供体药物的结构设计中获得缺氧激活型前药,是提高这类药物疗效和减少副作用的有效方法。硝基还原酶(NTR)存在于哺乳动物的心脏、肝、肾、肺、脑组织中,它可在厌氧条件下由NADPH和NADH提供氢催化硝基芳香族化合物还原。因此,硝基芳香族化合物是一种公认的缺氧激活基团,可用于缺氧激活型前药的设计。这是因为缺氧细胞中的NTR可选择性地还原芳环上的硝基,进而通过分子内的电子转移促进前药释放出活性药物基团。由于NTR在缺氧细胞中高表达,可有效促进前药中的活性药物基团在缺氧微环境中集中释放,因此利用硝基芳香族化合物的缺氧激活特性,将其与NO供体结合得到前药,使其在缺氧激活下释放足量的NO,对治疗冠心病等心血管疾病具有重要意义。
发明内容
发明目的:为了解决现有NO供体药物治疗心肌缺氧损伤疗效不佳、副作用大等问题,本发明旨在提供一类可在缺氧微环境中有效改善心肌缺氧损伤的NO供体化合物及其制备方法、药物组合物和应用。
技术方案:作为本发明涉及的第一方面,本发明的NO供体化合物具有式I的结构:
其中:
R1为硝基时,R2为氢、卤素或C1-C4烷基,R3为氢、卤素或C1-C4烷基;
R2为硝基时,R1为氢、卤素或C1-C4烷基,R3为氢、卤素或C1-C4烷基。
本发明将缺氧激活基团硝基芳香族化合物通过连接基团与NO供体分子键联,得到缺氧激活型NO供体化合物。
优选,所述结构中:
R1为硝基,R2为氢、卤素或甲基,R3为氢。
更具体地,所述的NO提供化合物选自以下任一化合物:
作为本发明涉及的第二方面,所述的NO供体化合物的制备方法为将化合物1与化合物2经酰化反应得到化合物I,具体合成步骤如下:
(1)4-羟基(N-甲基)苯胺半硫酸盐与NaNO2在乙酸存在下反应得化合物1;步骤(i)中,反应温度为0℃,溶剂为乙酸(AcOH),反应时间为3h;
(2)苯甲醇衍生物与二(三氯甲基)碳酸酯(三光气,BTC)在N,N-二异丙基乙胺(DIPEA)存在下反应得化合物2;步骤(ii)中,反应温度为室温,溶剂为四氢呋喃(THF),反应时间为5h;
(3)化合物1和化合物2在N,N-二异丙基乙胺存在下反应得产物I;步骤(iii)中,反应温度为室温,溶剂为二氯甲烷(DCM),反应时间为5h。
其中,R1、R2、R3的定义如前所述。
作为本发明涉及的第三方面,本发明的药物组合物包含所述NO供体化合物以及药学上可接受的载体。
所述NO供体化合物可以添加药学上可接受的载体制成常见的药用制剂,如片剂、胶囊、糖浆、悬浮剂或注射剂,制剂可以加入香料、甜味剂、液体/固体填料、稀释剂等常用药用辅料。
作为本发明涉及的第四方面,本发明的NO供体化合物、药物组合物可制备为治疗心肌缺氧损伤类疾病的药物,上述化合物为缺氧激活型NO供体化合物,用于改善缺氧条件下的心肌细胞活力,具体用于治疗冠心病。上述化合物可在缺氧微环境中的细胞里释放NO,有效改善心肌缺氧损伤。
有益效果:与现有技术相比,本发明具有如下显著优点:
(1)该类NO供体化合物、药物组合物可在缺氧条件下有效释放NO,释放量最高达40%以上,并且可以改善心肌细胞的活力,在体内外均可作为缺氧激活型NO供体;
(2)该类NO供体化合物、药物组合物应用广泛,可制备为治疗心肌缺氧损伤类疾病的药物;所述药物在细胞水平和动物水平均可以发挥药效,并且治疗效果更优异;
(3)化合物制备方法简便、易操作。
附图说明
图1a为化合物在常氧条件下对心肌细胞H9c2的活力改善作用;
图1b为化合物在缺氧条件下对心肌细胞H9c2的活力改善作用;
图2为化合物I1在缺氧造模小鼠心脏中的NO释放水平;
图3为小鼠心脏中的mTORC1、TSC2-P蛋白表达水平。
具体实施方式
下面结合实施例对本发明的技术方案作进一步说明。
实施例1:N-甲基-N-亚硝基对苯酚(化合物1)的制备
避光条件下向50mL乙酸中加入4-羟基(N-甲基)苯胺半硫酸盐(1.722g,10.0mmol)并超声使之溶解。在冰水浴冷却下向乙酸溶液中滴入溶于10ml水的亚硝酸钠(1.380g,20.0mmol)溶液,滴加完后冰水浴下继续反应3h。反应完后将反应液转移至烧杯中,加入50mL水,用饱和碳酸氢钠水溶液调节pH至7,然后用乙酸乙酯萃取该水溶液,合并有机相,无水硫酸钠干燥后,旋干得产物1.46g,产率96%。
1H NMR(600MHz,DMSO-d6):δ9.79(s,1H),7.41(d,J=8.8Hz,2H),6.89(d,J=8.8Hz,2H),3.38(s,3H)ppm.
实施例2:氯甲酸对硝基苄酯(化合物2a)的制备
将对硝基苄醇(0.168g,1.1mmol)和BTC(0.296g,1.0mmol)溶于20mL无水四氢呋喃中,在冰水浴冷却下加入N,N-二异丙基乙胺(0.142g,1.1mmol),在氮气保护下反应30min。然后在室温下反应5h。反应完毕,浓缩反应液,用少量无水四氢呋喃除去多余的光气,加无水二氯甲烷后直接用于下一步反应。
实施例3:4-((甲基亚硝基)氨基)苯基(4-硝基苄基)碳酸酯(化合物I1)的制备
将化合物1(0.152g,1.0mmol)和N,N-二异丙基乙胺(0.258g,2.0mmol)溶于20mL无水二氯甲烷中,在冰水浴冷却下将实施例2中获得的含化合物2a的无水二氯甲烷溶液缓慢滴入上述溶液中。滴完后撤去冰水浴,室温下反应5h。反应液分别用0.5M稀盐酸、水、饱和食盐水各洗涤3次,分出有机相,用无水硫酸钠干燥过夜,然后旋蒸浓缩,得到黄色固体,用乙酸乙酯和石油醚混合溶剂重结晶,得淡黄色晶体285mg,产率86%。
1H NMR(600MHz,DMSO-d6):δ8.28–8.30(m,2H),7.74–7.76(m,2H),7.70–7.72(m,2H),7.45–7.48(m,2H),5.46(s,2H),3.44(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ153.15,150.02,147.87,143.07,140.37,129.32,124.15,122.79,121.20,69.03,32.14ppm.HRMS(m/z)(ESI):calcd for C15H14N3O6[M+H]+:332.08,found:332.11.
实施例4:4-((甲基亚硝基)氨基)苯基(2-氯-4-硝基苄基)碳酸酯(化合物I2)的制备
参照实施例2和3所述方法,采用2-氯-4-硝基苄醇为原料,得到化合物I2,淡黄色晶体,产率23%。
1H NMR(600MHz,DMSO-d6):δ8.38-8.39(d,J=2.3Hz,1H),8.28-8.30(dd,1H),7.88-7.90(d,J=8.5Hz,1H),7.71–7.72(m,2H),7.46-7.48(m,2H),5.49(s,2H),3.44(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ152.99,149.95,148.49,140.41,140.18,133.62,131.17,124.78,122.96,122.77,121.25,66.92,32.20ppm.HRMS(m/z)(ESI):calcd forC15H13ClN3O6Na[M+Na]+:388.03,found:388.10.
实施例5:4-((甲基亚硝基)氨基)苯基(2-甲基-4-硝基苄基)碳酸酯(化合物I3)的制备
参照实施例2和3所述方法,采用2-甲基-4-硝基苄醇为原料,得到化合物I3,淡黄色晶体,产率45%。
1H NMR(600MHz,DMSO-d6):δ8.15-8.16(d,J=2.2Hz,1H),8.10-8.14(dd,J=8.4,2.4Hz,1H),7.71-7.73(d,J=2.2Hz,1H),7.68–7.70(m,2H),7.45–7.48(m,2H),5.44(s,2H),3.44(s,3H),2.47(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ153.11,150.01,147.78,141.17,140.37,139.16,129.71,125.06,122.80,121.49,121.21,67.66,32.17,18.77ppm.HRMS(m/z)(ESI):calcd for C16H15N3O6[M+H]+:346.10,found:346.10.
实施例6:4-((甲基亚硝基)氨基)苯基(2-硝基苄基)碳酸酯(化合物I4)的制备
参照实施例2和3所述方法,采用2-硝基苄醇为原料,得到化合物I4,淡黄色晶体,产率73%。
1H NMR(600MHz,DMSO-d6):δ8.17-8.19(dd,1H),7.85-7.88(m,1H),7.79–7.80(m,1H),7.70–7.73(m,2H),7.68–7.69(m,1H),7.45–7.47(m,2H),5.65(s,2H),3.44(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ153.04,149.98,147.82,140.40,134.85,130.81,130.25,130.06,125.49,122.77,121.24,67.09,32.16ppm.HRMS(m/z)(ESI):calcd for C15H14N3O6[M+H]+:332.09,found:332.02..
实施例7:4-((甲基亚硝基)氨基)苯基(2-硝基-4-氯苄基)碳酸酯(化合物I5)的制备
参照实施例2和3所述方法,采用2-硝基-4-氯苄醇为原料,得到化合物I5,淡黄色晶体,产率46%。
1H NMR(600MHz,DMSO-d6):δ8.26-8.27(d,J=2.2Hz,1H),7.94-7.96(dd,1H),7.81-7.83(d,J=8.4Hz,1H),7.70–7.72(m,2H),7.45–7.46(m,2H),5.62(s,2H),3.44(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ152.94,149.96,148.47,140.42,134.51,134.21,131.84,129.81,125.32,122.75,121.24,66.53,32.15ppm.HRMS(m/z)(ESI):calcd forC15H13ClN3O6Na[M+Na]+:388.03,found:388.00.
实施例8:4-((甲基亚硝基)氨基)苯基(2-硝基-4-溴苄基)碳酸酯(化合物I6)的制备
参照实施例2和3所述方法,采用2-硝基-4-溴苄醇为原料,得到化合物I6,淡黄色晶体,产率33%。
1H NMR(600MHz,DMSO-d6):δ8.36-8.37(d,J=2.1Hz,1H),8.07-8.09(dd,1H),7.73-7.75(d,J=8.3Hz,1H),7.70–7.72(m,2H),7.44–7.46(m,2H),5.60(s,2H),3.44(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ152.94,149.96,148.49,140.42,137.45,131.94,130.19,128.03,122.75,122.16,121.24,66.58,32.15.HRMS(m/z)(ESI):calcd forC15H13BrN3O6[M+H]+:431.98,found:431.90.
实施例9:4-((甲基亚硝基)氨基)苯基(2-硝基-4-甲基苄基)碳酸酯(化合物I7)的制备
参照实施例2和3所述方法,采用2-硝基-4-甲基苄醇为原料,得到化合物I7,淡黄色晶体,产率51%。
1H NMR(600MHz,DMSO-d6):δ8.00–8.01(m,1H),7.70–7.72(m,2H),7.66-7.67(d,J=0.9Hz,2H),7.43–7.46(m,2H),5.60(s,2H),3.44(s,3H),2.44(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ153.04,149.99,147.77,140.57,140.38,135.29,130.22,127.75,125.56,122.74,121.20,67.02,32.12,20.74ppm.HRMS(m/z)(ESI):calcd for C16H16N3O6[M+H]+:346.10,found:345.90.
实施例10:4-((甲基亚硝基)氨基)苯基(2-硝基-5-氯苄基)碳酸酯(化合物I8)的制备
参照实施例2和3所述方法,采用2-硝基-5-氯苄醇为原料,得到化合物I8,淡黄色晶体,产率37%。
1H NMR(600MHz,DMSO-d6):δ8.21-8.23(d,J=8.8Hz,1H),7.83-7.84(d,J=2.3Hz,1H),7.76-7.79(dd,1H),7.71–7.73(m,2H),7.46–7.48(m,2H),5.65(s,2H),3.44(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ152.82,149.98,146.36,140.43,139.48,133.27,130.05,129.67,127.63,122.76,121.23,66.56,32.14ppm.HRMS(m/z)(ESI):calcd forC15H13ClN3O6Na[M+Na]+:388.03,found:388.00.
实施例11:4-((甲基亚硝基)氨基)苯基(2-硝基-5-甲基苄基)碳酸酯(化合物I9)的制备
参照实施例2和3所述方法,采用2-硝基-5-甲基苄醇为原料,得到化合物I9,淡黄色晶体,产率48%。
1H NMR(600MHz,DMSO-d6):δ8.09-8.11(d,J=8.4Hz,1H),7.72-7.73(d,J=2.2Hz,1H),7.71-7.72(d,J=2.3Hz,1H),7.57–7.58(m,1H),7.48–7.49(m,1H),7.46-7.47(d,J=2.3Hz,1H),7.45-7.46(d,J=2.2Hz,1H),5.63(s,2H),3.44(s,3H),2.47(s,3H)ppm.13C NMR(150MHz,DMSO-d6):δ153.00,150.01,145.93,145.49,140.40,130.95,130.47,130.26,125.70,122.78,121.24,67.21,32.15,21.53ppm.HRMS(m/z)(ESI):calcd for C16H15N3O6Na[M+Na]+:368.09,found:368.10.
实施例12:Griess法检测化合物在常氧或缺氧下与心肌细胞H9c2作用后的NO释放水平
将心肌细胞H9c2复苏,使用DMEM培养基进行培养,放入二氧化碳培养箱中培养使其贴壁生长。待细胞达到合适密度后,接种于多孔板中,放入二氧化碳培养箱中,在37℃、5%CO2及饱和湿度条件下培养24h至细胞贴壁,弃掉上清液,加入新鲜DMEM培养基2mL,然后加入一定浓度(5、10、15μM)的化合物和对照品药物硝酸异山梨酯。在常氧培养箱(37℃、21%O2)或缺氧培养箱(37℃、1%O2)培养4h之后,去除上清液,然后将板内细胞分别收集于1.5mL离心管中,1000rpm,离心5min,弃掉上清液,加入1mL PBS重悬细胞,再次离心,弃掉PBS,离心管中加入100μL细胞裂解液(NO测定专用),冰上放置半分钟,然后4℃下13300rpm离心5min,收集上清液。取50μL上清液于96孔板中,每种样品设置三个平行组,先后加入50μLGriess试剂I和50μLGriess试剂II。在540nm波长下用全波长酶标仪测定每孔OD值,NO浓度通过标准曲线计算出,结果见表1和表2。
表1.常氧下心肌细胞H9c2经化合物处理4h后的NO释放量
*.NO释放量=实测NO浓度/计算NO浓度,数据以三次独立实验的平均SD表示:*p<0.05,
**p<0.01;
a.表示未测,b.按释放量的1/2计算。
表2.缺氧下心肌细胞H9c2经化合物处理4h后的NO释放量
*.NO释放量=实测NO浓度/计算NO浓度,数据以三次独立实验的平均SD表示:*p<0.05,
**p<0.01;
a.表示未测,b.按释放量的1/2计算。
表1和表2的数据表明,在常氧下不同浓度的化合物处理心肌细胞后导致NO在细胞中的释放量很小,都低于化合物I2的最大释放量(<3.34%,10μM);但在缺氧下,除化合物I5-I9外,不同浓度的化合物I1-I4处理心肌细胞后可有效导致NO在细胞中的释放,释放量在20.15%~45.45%之间,表现为缺氧激活型NO供体。对照品硝酸异山梨酯(ISDN)无论在常氧还是缺氧下处理心肌细胞后,均释放出一定量的NO;其在常氧下导致NO在细胞中的释放量较大,高达41.63%(10μM),在缺氧下也可导致NO在细胞中的释放,但释放量小于常氧下的释放量,低于化合物I2和I3的释放水平。
实施例13:化合物在常氧或缺氧下对心肌细胞H9c2的活力改善作用
用5mL PBS清洗细胞两次,加入1mL胰酶消化单层培养心肌细胞H9c2,用含血清的培养液配成单个细胞悬液,以每孔5000-10000个细胞接种于96孔培养板中,每孔培养基体积100μL,边缘孔用灭菌后的纯水填充。将培养板移入二氧化碳培养箱中,在37℃、5%CO2及饱和湿度条件下培养24h至细胞贴壁,将孔内的100μL培养基吸出,加入50μL新鲜培养基,分别给予不同浓度的化合物和对照品药物硝酸异山梨酯。每孔加药50μL,设3个平行组和1个常氧不加药组作为对照。(浓度梯度为10,1,0.1,0.01,0.001μM)。常氧培养组在正常培养箱中于5%CO2、37℃条件下孵育4h;缺氧组置于缺氧培养箱(O2浓度≤1%)中37℃条件下孵育4h,培养完成后每孔加入10μL的CCK8试剂,常氧培养箱中继续培养4h。终止培养,在酶标仪450nm处测量各孔的吸光值,计算各浓度下心肌细胞的细胞存活率,结果见图1a和图1b。
在常氧条件下(见图1a),化合物I1-I9随着浓度的增加,除化合物I4在1μM下对细胞的活力有微小提高外,其它化合物对细胞的活力没有任何改善,相反它们在高浓度10μM时对细胞的活力还有所影响,表现出较小的毒性。在缺氧条件下(见图1b),化合物I1-I4在0.001~10μM浓度范围内均能显著恢复缺氧细胞的活力,并且随着化合物浓度的增加有所提高,而化合物I5-I9对恢复缺氧细胞活力的没有明显作用。对照药物硝酸异山梨酯在常氧条件下对细胞的活力没有任何改善,在缺氧条件下,仅在高浓度时表现出一定的能力,但不如化合物I1-I4。结合表1和表2数据,该类缺氧激活型NO供体化合物I1-I4在缺氧条件下,可有效释放NO,在一定浓度区间可改善心肌细胞的活力,其活性优于现有药物硝酸异山梨酯。该有益效果也在动物水平实验中得以验证。
实施例14:NO检测试剂盒检测化合物I1在缺氧造模小鼠心脏中NO的释放水平
(a)药品与试剂及实验动物
NO检测试剂盒(碧云天生物技术有限公司,上海),缺氧造模及给药小鼠、空白对照组小鼠心脏组织匀浆,6-8周雄性昆明小鼠。
(b)实验原理
NO具有化学活性,在体内迅速转化为NO3 -和NO2 -,NO2 -进一步转化为NO3 -。采用griess试剂将NO3 -还原为NO2 -,NO2 -在540nm处有特征吸收,用酶标仪检测540nm处的吸光度,用标准曲线换算NO浓度。
(c)实验操作
(1)缺氧模型(85mg/kg异丙肾上腺素),给药组在缺氧造模前腹腔注射20mg/kg化合物I1;
(2)12000转离心15min收集心脏组织匀浆蛋白;
(3)配置NO检测试剂盒中的工作液,将工作液加入各组蛋白,孵育后用酶标仪检测,由此分析各组NO的含量,结果见图2。
如图2所示,在对小鼠进行缺氧造模及给药后,化合物I1组心脏内NO水平显著高于其它两组。
实施例15:Western blot法研究化合物I1对心肌缺氧小鼠的心肌损伤标志物蛋白表达水平的调节作用
(a)药品与试剂及实验动物
Western Blot制胶试剂盒(碧云天生物技术有限公司,上海)、蛋白定量用BCA检测试剂盒(碧云天生物技术有限公司,上海),电离缓冲液、湿转液、一抗(anti-TSC2-P,Abgent,1:1000,A-AP3825a;anti-mTORC1,Abcam,1:1000,ab120224;anti-GAPDH,BioworldTechnology,1:500,AP0063)、二抗(Goat Anti-Rabbit IgG(H+L)HRP,1:3000,BioworldTechnology,BS13278),6-8周雄性昆明小鼠。
(b)实验原理
根据Western Blot条带分析蛋白表达水平的变化。
(c)实验操作
(1)提取小鼠心脏组织蛋白,12000转离心15min收集蛋白,用BCA试剂盒对蛋白进行定量,加入loading buffer沸水中煮5min备用;
(2)制备SDS-PAGE胶,上样分离蛋白条带;
(3)将蛋白条带转移到PVDF膜后,牛奶封闭、依次孵一抗、二抗,利用化学发光显影仪可视化蛋白条带,由此分析各组蛋白表达的变化,结果见图3。
如图3所示,由空白组小鼠、缺氧模型小鼠、给药加缺氧造模组小鼠的心脏分别提取蛋白样本进行Western blot实验。与空白组相比,缺氧模型组小鼠TSC2-P表达下调引起mTORC1蛋白表达显著上调,表明模型组出现明显的心肌损伤。20mg/kg化合物I1预处理的小鼠心脏mTORC1表达恢复到接近正常组水平,表明该化合物具有优良的抗心肌缺氧损伤作用。
Claims (10)
1.一种NO供体化合物,其特征在于,具有式I的结构:
其中:
R1为硝基时,R2为氢、卤素或C1-C4烷基,R3为氢、卤素或C1-C4烷基;
R2为硝基时,R1为氢、卤素或C1-C4烷基,R3为氢、卤素或C1-C4烷基。
2.根据权利要求1所述的NO供体化合物,其特征在于,所述结构中:
R1为硝基,R2为氢、卤素或甲基,R3为氢。
3.根据权利要求1所述的NO提供化合物,其特征在于,选自以下任一化合物:
4.一种权利要求1~3任一所述的NO供体化合物的制备方法,其特征在于,将化合物1与化合物2经酰化反应得到化合物I,
其中,R1、R2、R3的定义如权利要求1~3任一所述。
5.一种药物组合物,其特征在于,所述药物组合物包含权利要求1~3任一所述的NO供体化合物以及药学上可接受的载体。
6.一种权利要求1~3任一所述的NO供体化合物在制备治疗心肌缺氧损伤类疾病药物中的应用。
7.一种权利要求5所述的药物组合物在制备治疗心肌缺氧损伤类疾病药物中的应用。
8.根据权利要6或7所述的应用,其特征在于,所述化合物为缺氧激活型NO供体化合物。
9.根据权利要6或7所述的应用,其特征在于,所述药物用于改善缺氧条件下的心肌细胞活力。
10.根据权利要6或7所述的应用,其特征在于,所述疾病为冠心病。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210160994.8A CN116675620A (zh) | 2022-02-22 | 2022-02-22 | No供体化合物及其制备方法、药物组合物和应用 |
PCT/CN2023/074113 WO2023160344A1 (zh) | 2022-02-22 | 2023-02-01 | No供体化合物及其制备方法、药物组合物和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210160994.8A CN116675620A (zh) | 2022-02-22 | 2022-02-22 | No供体化合物及其制备方法、药物组合物和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116675620A true CN116675620A (zh) | 2023-09-01 |
Family
ID=87764785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210160994.8A Pending CN116675620A (zh) | 2022-02-22 | 2022-02-22 | No供体化合物及其制备方法、药物组合物和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116675620A (zh) |
WO (1) | WO2023160344A1 (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200507752B (en) * | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
GB2463883A (en) * | 2008-09-25 | 2010-03-31 | Pharma Patents Ltd | A pharmaceutical composition comprising an A-SMase inhibitor and an NO-donor |
-
2022
- 2022-02-22 CN CN202210160994.8A patent/CN116675620A/zh active Pending
-
2023
- 2023-02-01 WO PCT/CN2023/074113 patent/WO2023160344A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023160344A1 (zh) | 2023-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2291349T3 (es) | Derivados de acridina y su uso como medicamentos. | |
TW200536535A (en) | Indazole derivatives as inhibitors of hormone sensitive lipase | |
WO2015070766A1 (zh) | 一种n-苄基色胺酮衍生物及其制备方法和应用 | |
CN113292565B (zh) | 核苷类化合物及其制备方法和应用 | |
CN111559991B (zh) | 一种萘胺类化合物及其盐的制备方法和应用 | |
WO2023165165A1 (zh) | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 | |
WO2014169710A1 (zh) | 激酶抑制剂及治疗相关疾病的方法 | |
EP3403651B1 (en) | Isocorydine derivatives, preparation method and use thereof | |
CN116675620A (zh) | No供体化合物及其制备方法、药物组合物和应用 | |
CN115636817B (zh) | 含三唑环的靛红类衍生物及其制备方法与应用 | |
CN111093658A (zh) | 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物 | |
CN109096272B (zh) | 一种具有抗肿瘤活性的吲哚异羟肟酸类化合物及其应用 | |
CN108558986B (zh) | 含哌嗪结构的甘草次酸类衍生物及其制备方法与用途 | |
US11712434B2 (en) | Compound having anti-cancer effect, and preparation method therefor and use thereof | |
US10266489B2 (en) | Pyrrolic amide compound and preparation method and application thereof | |
CN111961043B (zh) | 乙酰唑胺衍生物及其制备方法和在制备治疗冠心病药物中的应用 | |
CN114133390A (zh) | 一种去氢骆驼蓬碱衍生物及其制备方法和应用 | |
CN104530081A (zh) | 雷帕霉素的氮杂环衍生物和用途 | |
CN110590779B (zh) | 3,10二对氯苯基6,12二氮杂四高立方烷类化合物及其合成方法、应用和药物组合物 | |
CN109293588A (zh) | 一种具有ido1/tdo双靶点的小分子化合物及其制备方法与应用 | |
US11351151B2 (en) | Compound having anticancer activity and preparation method and application | |
CN108689958B (zh) | 一种含有肼基的吲哚胺2,3-双加氧化酶抑制剂 | |
JPH01273598A (ja) | ミクソコッカスからの新規抗生物質 | |
CN113004222B (zh) | 一种氨基二硫代过酸硫酯类化合物及其制备方法和应用 | |
CN115466245B (zh) | 一种嘧啶联吡啶的异羟肟酸类衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |